Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Emergence Delirium 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Quality of Recovery 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myofibroma 1Endobronchial Metastases 1Delirium 1

Interventions

Gemcitabine 157Cisplatin 117pembrolizumab 81Cystectomy 46Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Docetaxel 39atezolizumab 33Magnetic Resonance Spectroscopy 33Radiotherapy 31durvalumab 30avelumab 26BCG Vaccine 26Specimen Handling 25Cystoscopy 24enfortumab vedotin 23Doxorubicin 23Fluorouracil 20Methotrexate 17Vinblastine 16Standard of Care 15Ipilimumab 14Filgrastim 145-aminolevulinic acid hexyl ester 14Transurethral Resection of Bladder 13Surgical Procedures, Operative 13Sunitinib 13Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × remimazolam × Clear all
NCT04532606 2025-07-30

Impact of Remimazolam on Prognosis After Bladder Cancer Surgery

Peking University First Hospital

Phase 4 Recruiting
1,128 enrolled
Genitourinary

Emergence Delirium, Urinary Bladder Neoplasms, Delirium

Data powered by HemOnc (CC BY 4.0) Colophon âš¡